C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School.
The institutes have led over 1,000 studies, published 5,500 manuscripts in the peer review literature (including 144 in the New England Journal) and have led 60 FDA submissions from their network of 7,000 sites worldwide. In 2014 and 2018 - 2020 Gibson was ranked as one of the world's most highly cited authors in all of science in the past decade by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 136,000 times, and he has an H index of 129 and an i10-index of 523.

Presentation(s):

• Discussion Panel: What Could International Registry/ARO/CRO Collaborations with Industry for EU MDR Submissions look Like?

  Saturday, February 25, 2023
  9:10 AM – 9:45 AM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• Panel Discussion

  Saturday, February 25, 2023
  11:00 AM – 11:20 AM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• ACS & AMI Management

  Saturday, February 25, 2023
  1:30 PM – 5:40 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• Factor Xi Inhibition: Preserving Normal Hemostasis and Preventing Pathologic Thrombosis post MI and Other Thrombotic Syndromes

  Saturday, February 25, 2023
  3:23 PM – 3:31 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• Panel Discussion: Thrombus Management and Anticoagulation

  Saturday, February 25, 2023
  4:35 PM – 4:53 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• ACS AND AMI 2023 CONTEMPORARY TOPICS

  Saturday, February 25, 2023
  4:53 PM – 5:40 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• Panel Discussion: ACS & AMI 2023 Contemporary Topics

  Saturday, February 25, 2023
  5:25 PM – 5:40 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• Poor Efflux or Exit of Cholesterol from Plaque is Associated with Worse Outcomes, and ApoA1 Enhances Efflux of Cholesterol from Plaque. Will a post MI Infusion Improve Outcomes? The AEGIS 2 Trial of >18,000 Patients

  Saturday, February 25, 2023
  4:06 PM – 4:14 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• CARDIOTUBE INTERVIEW: LBT: Clopidogrel Versus Aspirin In The Chronic Maintenance Period Following PCI in ACS

  Sunday, February 26, 2023
  8:15 AM – 8:25 AM ET

  Disclosure information not submitted.

• CARDIOTUBE INTERIVEW: Update on Recover and Protect 4 studies

  Sunday, February 26, 2023
  8:30 AM – 8:40 AM ET

  Disclosure information not submitted.

• CARDIOTUBE INTERVIEW: Latest Data from the RDN Studies

  Sunday, February 26, 2023
  8:45 AM – 8:55 AM ET

  Disclosure information not submitted.

• CARDIOTUBE INTERVIEW: LBT: The Navitor study

  Sunday, February 26, 2023
  9:00 AM – 9:10 AM ET

  Disclosure information not submitted.

• CARDIOTUBE INTERVIEW: LBT: 5 years outocme rom Surtavi and Corevalve Studies

  Sunday, February 26, 2023
  9:15 AM – 9:25 AM ET

  Disclosure information not submitted.

• CARDIOTUBE INTERIVEW: What you should know on Lp(a) studies

  Sunday, February 26, 2023
  2:15 PM ET

  Disclosure information not submitted.

• Forthcoming Pharmacological Agents and Trials that Could Impact your Practice late this Decade

  Monday, February 27, 2023
  3:01 PM – 3:09 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

• Panel Discussion | Forthcoming Pathways in Interventional Cardiology

  Monday, February 27, 2023
  3:30 PM – 3:45 PM ET

  Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Caladrius Bioscience: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Cytokinetics: Consultant (Ongoing); Daiichi Sankyo, Inc.: Consultant (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medtelligence: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); Microdrop: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); Miracor: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); Paratek: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Solstic Health/New Amsterdam Pharma: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)